Julie Taguchi
Hematology & Oncology · Santa Barbara, CANPI 1073615118
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,106 of the $2,388 with a category attached, or 88.2%. 30 manufacturers reported payments, led by Johnson & Johnson at 28.6% of the total. Reporting peaked in 2019 at $1,487 and has fallen 91.7% since, to $123 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 60 payments — averaging $39.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$684
- Genentech USA, Inc.$156
- Foundation Medicine, Inc.$151
- Bristol Myers Squibb$142
- Seagen Inc.$135
- Tesaro, Inc.$130
- plus $992 from 24 others
Across 300 payments — averaging $1460.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$225K
- Pfizer$143K
- Puma Biotechnology, Inc.$55K
- AstraZeneca$8K
- Amgen$4K
- Bristol Myers Squibb$885
- plus $471 from 1 others
What the payments were for
- Speaking & faculty fees$1516%
- Food & beverage$2,10688%
- Education$1326%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 8 | $684 |
| Genentech USA, Inc. | 4 | $156 |
| Foundation Medicine, Inc. | 1 | $151 |
| Bristol Myers Squibb | 2 | $142 |
| Seagen Inc. | 4 | $135 |
| Tesaro, Inc. | 3 | $130 |
| AbbVie | 3 | $117 |
| Sanofi | 2 | $109 |
| Regeneron Healthcare Solutions, Inc. | 1 | $96 |
| Clovis Oncology, Inc. | 1 | $93 |
| Daiichi Sankyo Inc. | 1 | $66 |
| Beigene USA, Inc. | 4 | $65 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $57 |
| AstraZeneca | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Novartis | 2 | $33 |
| Merck | 2 | $26 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| GSK | 1 | $25 |
| EUSA Pharma (US) LLC | 1 | $24 |
| Exelixis Inc. | 1 | $23 |
| Array Biopharma Inc | 1 | $19 |
| Flowonix Medical Incorporated | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Pfizer | 2 | $17 |
| Amgen | 1 | $17 |
| Mckesson Specialty Care Distribution, LLC | 1 | $15 |
| Bayer | 1 | $15 |
| Eisai Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARVYKTI$248
- FOUNDATIONONE$151
- FOUNDATIONONE HEME$151
- FOUNDATIONONE CDX$151
- FOUNDATIONFOCUS$151
- FOUNDATIONONE LIQUID$151
- TECVAYLI$125
- RYBREVANT$123
- Revlimid$118
- Venclexta$116
- IMBRUVICA$114
How this compares
$2,388 in reported general payments places this provider in the 40th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Santa Barbara
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.